← Back to patent-cliff list
Alpibectir
Tier C — Watch / tradeAlpibectir
BioVersys AG
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Transcription factors
Indications (approved)：结核性脑膜炎, Mycobacterium tuberculosis infection, Multidrug-resistant tuberculosis, Pulmonary tuberculosis
Regional status
US
-
EU
Phase I
2020-12-02
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Alpibectir?
Approved indications include: 结核性脑膜炎, Mycobacterium tuberculosis infection, Multidrug-resistant tuberculosis, Pulmonary tuberculosis.
When does the Alpibectir patent expire?
No public expiry year is available for Alpibectir yet; this page updates once verified.
How do I get a quote for Alpibectir intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03